Evrysdi (risdiplam) Patient Assistance Program
Don’t let the high cost of brand SMN2 splicing modifier disrupt your spinal muscular atrophy treatment. We help eligible patients access Evrysdi (risdiplam oral solution and tablets) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Evrysdi (risdiplam) is FDA-approved for treatment of spinal muscular atrophy (SMA) in adults and pediatric patients 2 months and older. Oral SMN2 pre-mRNA splicing modifier — increases functional SMN protein production by enhancing SMN2 exon 7 inclusion. Once-daily oral therapy distinguishes it from injectable/intrathecal (Spinraza) and one-time IV gene therapy (Zolgensma).
- Without assistance, Evrysdi costs commonly run approximately $25,000–$30,000 per month for adult dosing (annualized $300,000+); pediatric weight-based dosing varies.
- Through AffordMyPrescriptions, qualifying patients can access Evrysdi for a flat $69.95 per month.
- Other SMA therapies: nusinersen (Spinraza — intrathecal SMN2 splicing modifier, every 4 months after loading), onasemnogene abeparvovec-xioi (Zolgensma — one-time IV gene therapy delivering SMN1 cDNA; for pediatric patients <2 years, ~$2.1 million one-time cost). All three target SMN protein restoration through different mechanisms. Multi-disciplinary supportive care: respiratory support, nutrition support, physical/occupational therapy, mobility assistance, orthopedic management, psychosocial support, genetic counseling. SMN1 gene testing essential. Newborn screening for SMA now in all 50 US states.
What is Evrysdi Prescription Assistance Program?
The Evrysdi Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Evrysdi (used for spinal muscular atrophy in patients 2 months and older) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but enrollment involves detailed applications, neurology coordination, SMN1 gene testing documentation, and ongoing renewal — which can be overwhelming when managing a rare progressive neuromuscular disease.
At AffordMyPrescriptions, our Patient Advocates handle the entire Evrysdi PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your neurologist for required documentation (typically including SMN1 gene testing, motor function assessments, and clinical criteria), follow up with the manufacturer’s program until approval, manage your refills, and handle annual re-certification.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Evrysdi enrollment — from the initial application through ongoing refills and re-enrollment — so you never face a gap in your spinal muscular atrophy treatment.
Pharmacy Price Comparison
- Without assistance, Evrysdi costs tens of thousands of dollars per month at specialty pharmacies — adult dosing typically higher than pediatric weight-based dosing. Discount cards offer minimal relief at this price point, but a Patient Assistance Program can make this rare-disease therapy accessible if you qualify. The table below compares typical pricing to what you'd pay with our Evrysdi advocacy service:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Zolgensma gene therapy (alt) | ~$2.1M one-time | Alt one-time gene therapy |
| Walgreens | ~$29,000/mo | Save substantially |
| CVS Pharmacy | ~$30,000/mo | Save substantially |
| Walmart | ~$26,000/mo | Save substantially |
| Specialty pharmacy | ~$25,000/mo | Save substantially |
| Spinraza IT (alt) | ~$125,000/dose | Alt IT SMN2 modifier |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Evrysdi — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Evrysdi Prescription Program?
The Evrysdi Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy. Evrysdi’s oral administration offers a significant convenience advantage vs intrathecal Spinraza for ongoing therapy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Evrysdi assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Evrysdi is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Evrysdi:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $25,000–$30,000 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Evrysdi assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Evrysdi Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Evrysdi:
Evrysdi is an oral SMN2 pre-mRNA splicing modifier — promoting SMN2 exon 7 inclusion in the spliced mRNA and increasing functional SMN protein production. Available as an oral solution (for pediatric and adult use) and tablets. It distinguishes itself from intrathecal Spinraza and one-time IV Zolgensma gene therapy by oral administration. FIREFISH (infantile-onset), SUNFISH (Type 2/3), and JEWELFISH (pretreated) studies established efficacy across SMA types.
How It Works:
Spinal muscular atrophy (SMA) is a progressive autosomal recessive motor neuron disease caused by biallelic SMN1 gene deletion or mutation. Without functional SMN1, patients depend on the SMN2 paralog — but SMN2 produces predominantly truncated, non-functional SMN protein due to exclusion of exon 7. The amount of functional SMN protein determines disease severity (SMA Types 1–4). Risdiplam binds to two sites in SMN2 pre-mRNA — promoting inclusion of exon 7 in the mature SMN2 mRNA and increasing full-length, functional SMN protein. It distributes broadly including the CNS. Oral once-daily administration. Restored SMN protein improves motor neuron survival and function — reducing SMA progression and improving motor milestones, especially when initiated early.
Form and Use:
Evrysdi 0.75 mg/mL oral solution (reconstituted from powder), or 5 mg tablets. Dosing is weight-based and age-based: 2 months to <2 years (0.2 mg/kg once daily); 2 years to <20 kg (0.25 mg/kg); 20 kg and above (5 mg once daily). Take orally after a meal at approximately the same time each day. For G-tube administration, the oral solution can be given via tube with appropriate flushing. Continue indefinitely.
Generic Availability:
No generic Evrysdi. Other SMA therapies: nusinersen (Spinraza — intrathecal SMN2 splicing modifier, lumbar puncture every 4 months after loading), onasemnogene abeparvovec-xioi (Zolgensma — one-time IV AAV9 gene therapy delivering SMN1 cDNA; FDA-approved for pediatric SMA <2 years; ~$2.1 million one-time cost). All three target SMN protein restoration through different mechanisms — choice often by patient age, SMA type, anti-AAV9 antibody status (for Zolgensma eligibility), patient/family preference, insurance, and logistics. Multi-disciplinary supportive care: respiratory support (BiPAP, cough assist, ventilation), nutritional support (gastrostomy, weight management), physical/occupational therapy, orthopedic management (scoliosis, contractures), mobility devices, psychosocial and family support, and genetic counseling. SMN1 gene testing is essential for diagnosis. Newborn screening for SMA is now implemented in all 50 US states.
Warnings:
Use during pregnancy: limited human data — animal studies showed embryo-fetal toxicity; effective contraception during therapy and for some time after is recommended. Lactation: limited data — may pass into breast milk. Male fertility: animal data suggest possible effects. Drug interactions: minimal direct interactions but some considerations with strong CYP1A2 inhibitors and MATE substrates. Adverse reactions in adults: fever, diarrhea, rash, mouth ulcers, joint pain, urinary tract infection. In infants: upper respiratory tract infection, rhinitis, diarrhea, rash, fever. Overall well-tolerated. Vaccination plan per age and clinical context.
FAQ (Frequently Asked Questions)
How much does Evrysdi cost without insurance?
$25,000–$30,000 per month for adult dosing (5 mg daily). Pediatric weight-based dosing may be lower in absolute dollars but still very expensive. Annual cost commonly exceeds $300,000. Specialty pharmacy and Patient Assistance Programs are essential.
What is spinal muscular atrophy (SMA) and why is treatment important?
SMA is a rare autosomal recessive motor neuron disease caused by SMN1 gene defects — progressive muscle weakness, atrophy, respiratory compromise, and (in severe forms) early death. Modern SMN-restoring therapies (Evrysdi, Spinraza, Zolgensma) have transformed SMA into a disease with meaningful modification — especially when initiated early (newborn screening now in all 50 US states).
What is the difference between Evrysdi, Spinraza, and Zolgensma for SMA?
All three target SMN protein restoration through different mechanisms. Evrysdi (oral SMN2 splicing modifier) — once-daily oral, broad distribution, ongoing therapy. Spinraza (intrathecal SMN2 splicing modifier) — lumbar puncture every 4 months, ongoing. Zolgensma (one-time IV AAV9 gene therapy) — single infusion, approved for pediatric SMA <2 years, ~$2.1 million. Choice depends on age, SMA type, anti-AAV9 antibody status, family preferences, and logistics.
Can Evrysdi be used in infants?
Yes — approved for SMA in pediatric patients 2 months and older. Weight-based dosing of oral solution administered via syringe or G-tube. The FIREFISH trial demonstrated improved motor function and survival in infantile-onset SMA Type 1 patients.
What is newborn screening for SMA and why does it matter?
All 50 US states now include SMA in their newborn screening panels — detecting SMN1 gene deletion in dried blood spots within days of birth. Early diagnosis enables treatment initiation before symptom onset — when neuronal loss is minimal and outcomes are dramatically improved.
Take Control of Your Medication Costs
Disease-modifying SMN restoration therapy for spinal muscular atrophy should not be derailed by cost. Newborn screening enables early intervention with dramatic outcomes. Our Evrysdi advocacy team is ready to verify eligibility, complete the manufacturer application, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.